"Related: Yesterday, the WHO mistakenly posted draft documents of a Chinese study that showed remdesivir failed to improve patients' conditions.
Gilead countered that the study was underpowered for efficience since it was terminated early for low enrollment."
I'm not holding the stock.
Just had the feeling to post it!
Technically the stock remain strong!
Good-luck to all.
Gilead countered that the study was underpowered for efficience since it was terminated early for low enrollment."
I'm not holding the stock.
Just had the feeling to post it!
Technically the stock remain strong!
Good-luck to all.